Notice: This company has been marked as potentially delisted and may not be actively trading. Conatus Pharmaceuticals (CNAT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends CNAT vs. LIXT, NBY, MTNB, SBFM, ARAV, PTPI, VINC, ZVSA, SHPH, and ATXIShould you be buying Conatus Pharmaceuticals stock or one of its competitors? The main competitors of Conatus Pharmaceuticals include Lixte Biotechnology (LIXT), NovaBay Pharmaceuticals (NBY), Matinas Biopharma (MTNB), Sunshine Biopharma (SBFM), Aravive (ARAV), Petros Pharmaceuticals (PTPI), Vincerx Pharma (VINC), ZyVersa Therapeutics (ZVSA), Shuttle Pharmaceuticals (SHPH), and Avenue Therapeutics (ATXI). These companies are all part of the "medical" sector. Conatus Pharmaceuticals vs. Lixte Biotechnology NovaBay Pharmaceuticals Matinas Biopharma Sunshine Biopharma Aravive Petros Pharmaceuticals Vincerx Pharma ZyVersa Therapeutics Shuttle Pharmaceuticals Avenue Therapeutics Conatus Pharmaceuticals (NASDAQ:CNAT) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, community ranking, risk, institutional ownership and media sentiment. Which has more volatility and risk, CNAT or LIXT? Conatus Pharmaceuticals has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500. Does the media refer more to CNAT or LIXT? In the previous week, Conatus Pharmaceuticals' average media sentiment score of 0.00 equaled Lixte Biotechnology'saverage media sentiment score. Company Overall Sentiment Conatus Pharmaceuticals Neutral Lixte Biotechnology Neutral Does the MarketBeat Community prefer CNAT or LIXT? Conatus Pharmaceuticals received 537 more outperform votes than Lixte Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformConatus PharmaceuticalsOutperform Votes53779.67% Underperform Votes13720.33% Lixte BiotechnologyN/AN/A Which has better valuation and earnings, CNAT or LIXT? Lixte Biotechnology has lower revenue, but higher earnings than Conatus Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConatus Pharmaceuticals$21.72M0.04-$11.39MN/AN/ALixte BiotechnologyN/AN/A-$5.09M-$1.73-0.73 Is CNAT or LIXT more profitable? Lixte Biotechnology has a net margin of 0.00% compared to Conatus Pharmaceuticals' net margin of -52.42%. Conatus Pharmaceuticals' return on equity of -48.22% beat Lixte Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Conatus Pharmaceuticals-52.42% -48.22% -39.32% Lixte Biotechnology N/A -5,562.77%-130.48% Do institutionals and insiders believe in CNAT or LIXT? 15.2% of Conatus Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 11.3% of Conatus Pharmaceuticals shares are owned by company insiders. Comparatively, 14.8% of Lixte Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryConatus Pharmaceuticals beats Lixte Biotechnology on 7 of the 10 factors compared between the two stocks. Get Conatus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNAT vs. The Competition Export to ExcelMetricConatus PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$896,000.00$7.05B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.86%P/E Ratio-0.096.1426.7919.19Price / Sales0.04268.26435.1070.89Price / CashN/A65.6738.0134.83Price / Book0.056.707.644.62Net Income-$11.39M$138.98M$3.19B$246.06M Conatus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNATConatus PharmaceuticalsN/A$0.03flatN/A-91.4%$896,000.00$21.72M-0.0930LIXTLixte BiotechnologyN/A$1.45+3.6%N/A-45.3%$3.26MN/A-0.844Gap UpHigh Trading VolumeNBYNovaBay Pharmaceuticals1.6268 of 5 stars$0.66-1.3%$0.85+28.6%-87.8%$3.23M$14.73M-0.0130Analyst ForecastGap DownMTNBMatinas BiopharmaN/A$0.61+1.6%N/AN/A$3.10M$1.10M-0.1330Gap UpSBFMSunshine Biopharma1.7493 of 5 stars$2.51+0.8%$15.00+497.6%-59.9%$3.07M$32.96M-0.023ARAVAraviveN/A$0.04flatN/AN/A$2.95M$9.14M0.0020High Trading VolumePTPIPetros Pharmaceuticals0.6208 of 5 stars$0.29+18.4%N/A-92.1%$2.94M$5.82M-0.0620Gap DownHigh Trading VolumeVINCVincerx Pharma2.2424 of 5 stars$1.30+1.6%$40.00+2,976.9%-98.0%$2.91MN/A-0.0660ZVSAZyVersa Therapeutics2.4594 of 5 stars$1.24-4.6%$120.00+9,577.4%-80.0%$2.90MN/A0.002SHPHShuttle PharmaceuticalsN/A$0.70+1.3%N/AN/A$2.85MN/A-0.175Gap UpATXIAvenue Therapeutics1.2822 of 5 stars$1.36flatN/A-87.9%$2.79MN/A0.074Negative News Related Companies and Tools Related Companies Lixte Biotechnology Competitors NovaBay Pharmaceuticals Competitors Matinas Biopharma Competitors Sunshine Biopharma Competitors Aravive Competitors Petros Pharmaceuticals Competitors Vincerx Pharma Competitors ZyVersa Therapeutics Competitors Shuttle Pharmaceuticals Competitors Avenue Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CNAT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conatus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Conatus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
